Omar Ali, MD
Cardiovascular Disease · Dearborn, MINPI 1760665863
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,282 of the $13,074 with a category attached, or 78.6%. 45 manufacturers reported payments, led by Boston Scientific at 24.9% of the total. Reporting peaked in 2022 at $3,080 and has fallen 68.5% since, to $972 in 2025.
Across 366 payments — averaging $35.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Edwards Lifesciences$2K
- Abbott$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Johnson & Johnson$849
- Cardiovascular Systems Inc.$515
- plus $5K from 39 others
Across 21 payments — averaging $5226.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$100K
- Medtronic$10K
What the payments were for
- Travel & lodging$2,51119%
- Food & beverage$10,28279%
- Other$2822%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PASCAL$1,184
- Watchman$1,086
- PORTICO$444
- ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER$427
- WATCHMAN Access System$408
- LifeVest$336
- AMPLATZER Occluders$184
- Varithena Administration Pack$148
- Carto 3$146
- GENERAL ATHERECTOMY$146
- Flexitouch Plus$133
- ENTRE$133
- AMVUTTRA$125
- Peripheral Orbital Atherectomy System$122
- Assure WCD$119
- Edwards SAPIEN 3 Transcatheter Heart Valve$117
- DYNAGEN$115
- XARELTO$111
- LUX-Dx Insertable Cardiac Monitor$110
- LATITUDE$102
How this compares
$13,074 in reported general payments places this provider in the 80th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 59 | $66,917 |
| EliquisApixaban | 56 | $61,929 |
| EntrestoSacubitril/Valsartan | 45 | $42,223 |
| JardianceEmpagliflozin | 22 | $23,614 |
| BrilintaTicagrelor | 27 | $17,360 |
| FarxigaDapagliflozin Propanediol | 11 | $9,228 |
| Repatha SureclickEvolocumab | 14 | $7,258 |
| RhopressaNetarsudil Mesylate | 15 | $6,986 |
| ClopidogrelClopidogrel Bisulfate | 235 | $3,290 |
| Atorvastatin Calcium | 267 | $2,635 |
| Metoprolol Succinate | 181 | $2,431 |
| MitigareColchicine | 13 | $2,271 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 109 | $1,838 |
| Carvedilol | 153 | $1,547 |
| Losartan Potassium | 145 | $1,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $849 | $66,91759 claims |
| PfizerEliquis | $242 | $61,92956 claims |
| NovartisEntresto | $498 | $42,22345 claims |
| AstraZenecaBrilinta, Farxiga | $107 | $26,58838 claims |
| Boehringer IngelheimJardiance | $173 | $23,61422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Dearborn
- Elias KassabDearborn$172K
- Sohail HassanDearborn$121K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.